Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › ALLO

Allogene Therapeutics

ALLO Rare disease Lead: Phase 2 ★ Read the deep dive → 11 Biotech Distilled articles ↓ 36 filings & releases ↓ Cash $29.3M (Sep 30, 2026) ↓ 11 verdicts ↓ 2 timing quotes ↓
ImmunologyOncology Cell

Market cap $360M 346.5M shares (10-Q, Nov 3, 2026) × $1.04 close Nov 6, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. ALPHA3 corporate updateYear-end 2026ALPHA3 corporate update, Year-end 2026, routine
  2. ALLO-329 Ph1 interimNov 9, 2026ALLO-329 Ph1 interim, Nov 9, 2026, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (10 active programs)

Technology platforms

Dagger

Proprietary allogeneic CAR T platform technology incorporating CD70-targeting to address allogeneic rejection by targeting activated CD70-positive patient T cells; enables off-the-shelf CAR T development across oncology (hematological and solid tumors) and autoimmune disease; supports dual-CAR and site-specific genomic integration approaches.

Targets: CD70, BCMA, DLL3

Discontinued (1)

Capital (as filed)

Cash
$29.3M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$264M Sep 30, 2026
Long-term investments
$95.9M Sep 30, 2026
Operating cash flow
−$36.1M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$424M cash, runway 2029 per the update of Sep 30, 2026 — the company's own words as read there, not the filed figure

Offering documents (2)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (11)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (11 calls)

Every verdict Biotech Distilled has published on Allogene Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-03-27 Hold Allogene Therapeutics (ALLO) - Scientific Deep Dive for Lead and Pipeline Products Science is elegant but recent safety issues and protocol amendments introduce too much mechanistic risk to buy ahead of the April 2026 MRD clearance data.
  2. 2026-04-27 Speculative buy speculative UPDATE: Allogene Therapeutics (ALLO) - The Data Hit, The Raise Stung ALPHA3 MRD data cleanly retired the Conditioning Crisis bear case with 58.3% vs. 16.7% clearance and zero safety events, while the dilution-stung price offers a favorable entry; size as a lottery ticket, not a core position.
  3. 2026-05-14 Speculative buy speculative UPDATE: Allogene Therapeutics (ALLO) - The IP Sword Gets a Second Edge Clinical thesis still tracking after April MRD data, but IP overhang doubled with LTC arbitration joining Factor v. Cellectis; ALLO-329 timeline slipped six months; maintain lottery-ticket sizing.
  4. 2026-05-28 Speculative buy speculative UPDATE: Allogene Therapeutics (ALLO) - The Founder Hands Over the Keys CEO succession reads as orderly founder handoff to the architect of the April MRD data; no clinical or financial content changes; maintain lottery-ticket sizing.
  5. 2026-06-22 Watch UPDATE: Allogene Therapeutics (ALLO) - The ATM Arrives Two Months Early A $135M ATM filed two months after a fully funded raise, plus authorized shares doubled to 800M, caps near-term upside and signals dilution as a policy; clinical thesis intact but cap-table terms have moved.
  6. 2026-07-15 Speculative buy speculative UPDATE: Allogene Therapeutics (ALLO) - The Solid Tumor Wildcard Prints TRAVERSE JCO publication validates Dagger in a second indication with durable RCC responses and IEC-HS converted from lethal to manageable, creating a credible partnership path and favorable read-through to ALLO-329.
  7. 2026-07-29 Speculative buy speculative UPDATE: Allogene Therapeutics (ALLO) - The FDA Read the Same Data I Did RMAT and Fast Track granted after FDA reviewed the full ALPHA3 futility analysis, providing first external non-Allogene validation of the MRD signal and shortening the regulatory path at the margin.
  8. 2026-08-13 Speculative buy speculative UPDATE: Allogene Therapeutics (ALLO) - The ATM They Didn't Use Zero ATM shares sold through a 14% rally repairs the June cap-table objection; ALPHA3 site activation hit 80-site target six months early; manufacturing re-hiring underway; lottery-ticket sizing maintained.
  9. 2026-09-02 Speculative buy speculative UPDATE: Allogene Therapeutics (ALLO) - The CFO Walks Out With the ATM Still Loaded CFO retirement adds a watch item on cap-table continuity but contains no clinical or financial content; clinical thesis, cash position, and catalyst path are unchanged.
  10. 2026-09-30 Speculative buy speculative UPDATE: Allogene Therapeutics (ALLO) - TPG Heads for the Exit TPG's full exit at $1.55 is a sentiment negative but the shares came from a seller not the ATM, the overhang is now cleared, and the clinical thesis is untouched.
  11. 2026-11-07 Hold UPDATE: Allogene Therapeutics (ALLO) - Trading Below Cash, Three Days From the Dagger Test Moving from accumulating to waiting for November 9 ACR ALLO-329 data; the newly activated fludarabine arm adds real uncertainty to the Dagger story right before its first human test in autoimmune disease.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (36)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 6, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

13 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)